



innovation hub for the development of new therapies

About

The aim of preclinics discovery is to develop new ideas into product candidates.

Each project is handled like a start-up in the seed phase, with the advantage off a central management for all projects which leads to less overhead costs.

preclinics discovery has access to the complete research infrastructure of the preclinics holding.



Closing the gap between basic research and preclinical development.

- Connecting inventors, investors and industry
- Addressing all issues: pilot production, research model evaluation, study management etc.
- Saving the budget and lower the risk

For Industry

preclinics discovery offers pharmaceutical and life science companies collaborations on product development. If there is interest in one of the projects of our portfolio, there are different ways to participate:

License agreements, joint venture foundation or contract development

We are open for adding projects of a sponsor to our portfolio.

License Agreements

- Especially for mature projects
- Combination of milestone payments and royalties

Joint Venture Foundation

- Foundation of a spin-off company for further development
- Can be combined with additional shareholders / investors

Contract Development

- All generated IP is owned by the sponsor
- Combination of Fee-for Service and milestone payments

For Investors



We are especially interested in investors with expertise in the field of life science research and development.

Our focus is to find investors for the projects in our portfolio.

For preclinics discovery we are searching for strategic partners as long term shareholders.



For Inventors



preclinics discovery offers consultancy and the research management for early stage projects.

We will start with an evaluation phase. Depending on the effort there will be a fee for services performed during this evaluation phase.

During this phase preclinics discovery will charge a fee for the services performed.

The report of evaluation includes results and suggestions for the next development steps.


ImmUnion develops active and passive vaccines that use the potential of a patient's existing tetanus immunity to protect themselves against new pathogens.



VacciTag is the platform for novel vaccine formulations which are activated by tetanus immunity and thus become effective in a wide variety of routes.



ImmunoJunction are tiny antibody domains that connect to the tetanus antibodies and use them to protect against new pathogens.



ImmunoJunction and VacciTag can be formulated in different dosage forms:


- Nucleic Acids (DNA/RNA)
- Soluble Protein
- Live Bacteria Formulation




ImmunoJunction and **Vaccitag** are available by different administration routes. This opens new opportunities for active and passive vaccination.

Project 2 Plasmatecs / SERPIN^X

For the plasmatecs project preclinics acquired the IP of SerpinX, a spin-off from the University of Utrecht. The goal of plasmatecs is to develop new serine protease inhibitors for the treatment of blood clotting and inflammation disease, by modifying the cleavage site of serpins.



Example for the different inhibitory profile of plasmatecs mutants




The lead candidate ValSerin-A has a thrombolytic effect and prevents the formation of edema. It is currently being tested for treatment of severe inflammatory diseases.

Project 3 BoNTANA

BoNTANA stands for BoNT/A nucleic acid therapies and is a new concept to make treatments with neurotoxin agents more pleasant for the patient and to expand the possible range of BoNT/A applications.

With our approach the intervals for the treatments can be highly extended. This will be a huge benefit for patients with dystonia, paresis and hyperhidrosis, because the frequency of painful treatments will be reduced.



Together with preclinics research instruments we are developing a needle-free injection system for the painless treatment of large skin areas. This is an advantage in the dermatological practice and for gene immunization.

Project 4 Xenodoma

The vision is to provide organs for life-saving treatment in the event of organ failure. To reach this visionary goal we are already collaborating with clinics and public research institutions.

The production of therapeutic proteins, cells, tissues and organs in transgene animals is the focus of Xenodoma.

Xenodoma will build up the very special production capacities for this future-oriented technology. These capacities will be used as well for the production of recombinant antibodies, cells (e.g. human hepatocytes), tissues (e.g. aortic valves).



Additional services will be:

- intermediate hosting of human donor organs
- Quality assurance and accommodation of in vitro produced tissues and organs



We would be glad if you are interested in preclinics discovery.

Please contact:

Jonas Fünér (CEO)

jf@preclinics.com

+49 (0) 331-243433- 56